CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 33 enrolled
Drug / intervention
Bimatoprost +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02170662
NCT02170662Phase 2Completed
CompareCT.gov

Topical Bimatoprost Effect on Androgen Dependent Hair Follicles

Duke University·interventional·Posted Jun 23, 2014·Updated Sep 5, 2014

In Brief

A Phase 2 clinical trial evaluating Bimatoprost and Placebo for Male Pattern Hair Loss and Androgenetic Alopecia. Completed, enrolled 33 participants.

Detailed Summary

The purpose of this study is to determine the effect of bimatoprost solution on scalp hair growth. Bimatoprost 0.03% ophthalmic solution is currently approved by the FDA for treatment of glaucoma (Lumigan™) and for thickening of thin eyelashes (Latisse™). Bimatoprost 0.03% is not approved for the treatment of scalp hair loss and its use in this study is considered investigational which means it is still being tested in research studies. Thirty-three subjects were consented and screened, 9 entered and 9 completed the study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMale Pattern Hair Loss, Androgenetic Alopecia
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 23, 2014
Enrollment StartNov 1, 2009
Primary CompletionMay 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 12.0 years ago

Interventions

Bimatoprostdrug

Bimatoprost 0.03% ophthalmic solution as purchased from the manufacturer will be the active drug.

Placebodrug